Vyne Therapeutics executes 1-for-50 reverse stock split

• Vyne Therapeutics set a 1-for-50 reverse stock split tied to its proposed merger with Yarrow Bioscience.
• Post-split trading expected to start July 27 on Nasdaq under Yarrow Bioscience, ticker YARW.
• Split expected to cut outstanding shares to about 700,000 from about 33,400,000; authorized common stock unchanged.
• Fractional shares will be cashed out based on the July 23 Nasdaq close, adjusted for the split.
• Merger closing targeted for about July 24.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyne Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607210800PRIMZONEFULLFEED9765237) on July 21, 2026, and is solely responsible for the information contained therein.